Tubeless, Waterproof* Insulin Pump and
Wireless, Handheld Personal Diabetes Manager Make Switching from
Multiple Daily Injections to Pump Therapy Much Easier
BILLERICA, Mass. & ONTARIO, Canada--(BUSINESS WIRE)--Jul. 3, 2018--
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader
insulin pump technology with its Omnipod® Insulin
Management System (Omnipod System), today announced the Omnipod System
has been selected as the preferred insulin pump for individuals with
diabetes in the province of British Columbia, Canada, under the expanded
British Columbia PharmaCare insulin pump program.
This press release features multimedia. View the full release here:
Insulet’s Omnipod Insulin Management System; Waterproof*, tubeless Pod, and handheld wireless Personal Diabetes Manager with built in BGM (Photo: Business Wire)
Effective today, an individual who requests an initial or replacement
insulin pump and meets the eligibility criteria will receive coverage
for the Omnipod System. As the only tubeless insulin pump sold in
Canada, the Omnipod System delivers continuous insulin for up to three
days without the use of tubes, eliminates the burden of multiple daily
injections, and is now available for all age groups in British Columbia.
“We are thrilled with the British Columbia Ministry of Health’s decision
to select Omnipod as its preferred insulin pump,” said Bret Christensen,
Chief Commercial Officer. “Access to appropriate technology is paramount
for people living with diabetes and is a key priority for Insulet. This
decision is a huge win for individuals with diabetes who may now
experience the tremendous benefits of our differentiated Omnipod System.
This news, together with our assuming direct commercial operations in
Europe, further solidifies our position as a global provider for optimal
It is estimated there are 18,300 people living with Type 1 diabetes in
British Columbia, according to Diabetes Canada, with approximately 25%
of this population using insulin pump therapy.
“This is a great development for British Columbians living with
diabetes,” said Dr. Tom Elliott, Clinical Associate Professor at UBC and
Medical Director at BCDiabetes.ca. “With the expansion of coverage
beyond age 25, every individual on intensive insulin therapy meeting the
medical criteria is now eligible for pump coverage. In my practice
alone, that means over 800 additional patients are now able to access
insulin pump therapy.”
Additional details on the British Columbia PharmaCare insulin pump
program can be found here.
*The Pod has a waterproof IPX8 rating for up to 25 feet for 60
minutes. The PDM is not waterproof.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a
needle. Insulet also leverages the unique design of its Pod, by
tailoring its Omnipod technology platform for the delivery of
non-insulin subcutaneous drugs across multiple therapeutic areas.
Founded in 2000, more than 140,000 users across the globe rely on
Insulet’s Omnipod Insulin Management System to bring simplicity and
freedom to their lives.
On July 1, 2018, Insulet assumed direct operations of its Omnipod
Insulin Management System in Europe, including sales, marketing,
training and customer support activities. This allows Insulet to be
closer to the diabetes community and identify opportunities to support
European customer needs over the long-term, as Insulet does in the
United States and Canada.
For more information, please visit: www.insulet.com
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations, intentions, beliefs or
strategies regarding the future. These forward-looking statements are
based on its current expectations and beliefs concerning future
developments and their potential effects on Insulet. There can be no
assurance that future developments affecting Insulet will be those that
it has anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 22, 2018 in the section entitled
"Risk Factors," and in its other filings from time to time with
the Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its assumptions
prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.
© 2018 Insulet Corporation. Omnipod and the Omnipod logo are trademarks
or registered trademarks of Insulet Corporation. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180703005014/en/
Source: Insulet Corporation
Investor Relations and Corporate
Deborah R. Gordon, 978-600-7717
President, Investor Relations and Corporate Communications
Natalie MacMillan, 978-600-7421
Manager, Global Public Relations & Field Programs